Chitosan-Based Biomaterials and Orthobiologics for Regenerative Medicine
PROJECT COST:
PRIMA CONTRIBUTION:
PROJECT DETAILS:
Derived from a biomaterial invented at Polytechnique Montréal, a technology named Ortho-R was acquired in 2015 by ChitogenX (formerly Technologies Ortho Régénératives, Ortho RTI), which has since collaborated with Polytechnique Montréal to continue its development. A clinical study for tendon tear repair began in 2021 in the United States. Further R&D is required to advance Ortho-R and meet regulatory agency requirements. The company also aims to explore new applications for Ortho-R and to develop additional biomaterials for regenerative medicine. Target applications include soft tissue repair/regeneration (tendon, meniscus, cartilage, ligament) and treatment of chronic wounds and osteoarthritis, addressing major unmet medical needs.
The main objectives of the project are:
- To optimize and scale up Ortho-R manufacturing processes;
- To elucidate mechanisms of action and characterize the structural and mechanical properties of repair tissues generated using Ortho-R;
- To evaluate the potential of Ortho-R for chronic wound treatment and ligament repair;
- To develop new biomaterials, including those aimed at osteoarthritis treatment.
The combined markets for these biomaterial applications exceed $10 billion per year. This research project will generate new knowledge, unique expertise, and innovative technologies in regenerative medicine.
Ortho-RTI will continue the development of Ortho-R and create new biomaterials to expand its product portfolio. Biomomentum will develop standardized mechanical testing methods and contribute to training future employees. KABS will generate new expertise in biomaterial production, potentially leading to job creation if Ortho-R reaches commercialization.
Approximately 20 highly specialized jobs in the life sciences sector will be created, and 62 highly skilled personnel will receive professional training. Innovative regenerative medicine technologies, entirely developed in Quebec, will be made available to the population while reinforcing Quebec’s leadership in the life sciences sector.
SECTORS:
INDUSTRIAL PARTNERS:
RESEARCH PARTNERS:
